In March 2020 the world officially released its first approach to the coronaviral pandemic to explain the rationale for using hydroxychloroquine. It was also believed to calm down the immune system during viral infections. The FDA warned using hydroxychloroquien for SARS-CoV-2. In this short letter we address why the FDA discontinued the treatment of the novel coronavirus with hydroxychloroquine.
Cite this article:
Ali Adel Dawood. Reasons for discontinuing the use of Hydroxychloroquine in the treatment of the Novel Coronavirus. Asian Journal of Pharmaceutical Analysis. 2021; 11(2):179-0. doi: 10.52711/2231-5675.2021.00030
Ali Adel Dawood. Reasons for discontinuing the use of Hydroxychloroquine in the treatment of the Novel Coronavirus. Asian Journal of Pharmaceutical Analysis. 2021; 11(2):179-0. doi: 10.52711/2231-5675.2021.00030 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2021-11-2-20
1. Nowell, J. and Quaranta, V. Chloroquine affects biosynthesis of Ia molecules by inhibiting
dissociation of invariant (gamma) chains from alpha-beta dimers in B cells. J Exp Med. 1985; 162, 1371-1376.
2. Emy J, and Rani J. Alcohol and Covid – 19. Int. J. of Advances in Nur. Management. 2020; 8(4): 341-344.
3. Naresh V. A Review of the 2019 Novel Coronavirus (COVID-19) Pandemic. Asian J. Pharm. Res. 2020; 10(3): 233-238.
4. Manisha R, Pradnya K. Coronavirus Disease: A Review of a New Threat to Public Health. Asian J. Pharm. Res. 2020; 10(3): 241-244.
5. Savarino, A., Boelaert, J.R., Cassone, A., Majori, G. and Cauda, R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2020; 3, 722-727. Doi: 10.1016/S1473-3099(03)00806-5.
6. Pankaj S, Pankaj M, Pushpendra K, and Himanshu T. Plant Immunobooster against COVID-19. Res. J. Pharmacognosy and Phytochem. 2020; 12(3): 174-177.
7. Dawood A, Altobje M. Inhibition of N-linked Glycosylation by Tunicamycin May Contribute to The Treatment of SARS-CoV-2. Microbiol Path. 2020; 149:104586. https://doi.org/10.1016/j.micpath.2020.104586.
8. Yao X, Ye F, Zhang M, Cui C, Huang B, and Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; Mar 9: ciaa237. Doi:10.1093/cid/ciaa237.
9. Rother N, Yanginlar C, Lindeboom R, Bekkering S, Van Leent M, and Buijsers B, et al. Hydroxychloroquine inhibits trained immunity – implications for COVID-19. medRixv. 2020; June; 9. Doi.org/10.1101/2020.06.08.20122143.
10. Ritika G. The Management of Coronavius Pandemic 2019-2020. Asian J. Pharm. Res. 2020; 10(4):327-330.
11. Nikhat F, Thouheed A, Moid A. Sars-CoV-2leader-RNA-primed Transcription and RNA-Splicing prevention, control and Treatment. Asian J. Research Chem. 2020; 13 (4):291-298.
12. Dharshini J, Bruce S, Shanmugasundaram S. Dietary Flavonoids as competitive Inhibitors of covid 19 major protease. Res. J. Pharmacognosy and Phytochem. 2020; 12(4):261-266.
13. Dawood A, Alnori H. Tunicamycin Anticancer Drug May Reliable to Treat Coronavirus Disease-19. OAMJMS. 2020; 8(T1):129-133. https://doi.org/10.3889/oamjms.2020.4954.